EMV CAPITAL PLC

DEEP TECH | LIFE SCIENCES | SUSTAINABILITY



FINAL RESULTS

For the year ended 31 December 2024

June 2025

DEEP TECH | LIFE SCIENCES | SUSTAINABILITY

DISCLAIMER

This presentation (and any information contained in any oral presentation accompanying it) (**Presentation**) has been prepared by EMV Capital plc (**Company**). This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (**FSMA**). This Presentation should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Any person who receives this Presentation should not rely or act upon it. Any person who is in any doubt about this Presentation should consult a person duly authorised for the purposes of FSMA who specialises in the acquisition of shares and other securities.

Whilst the information contained in this Presentation has been prepared in good faith, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as **Information**) and liability therefore is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation. All statements of opinion and/or belief contained in this Presentation and all views expressed represent the directors' own current assessment and interpretation of information available to them as at the date of this Presentation.

This Presentation has not been fully or independently verified and is subject to material updating, revision and further amendment. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the recipient with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation which may become apparent.

This Presentation contains certain forward-looking statements that involve substantial risks and uncertainties, and actual results and developments may differ materially from those expressed or implied by these statements. These forward-looking statements include, but are not limited to, statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, prospects, growth, forecasts, projections, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Therefore, actual results and future events could differ materially from those anticipated in such statements. No representation is made or assurance given that such statements or views are correct or that the objectives of the Company will be achieved. The reader is cautioned not to place reliance on these statements or views and no responsibility is accepted by the Company or any of its shareholders, directors, officers, agents, employees or advisers in respect thereof.

This Presentation does not constitute an offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever.

Neither this Presentation nor any copy of it may be: (a) taken or transmitted into Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or the United States of America (each a **Restricted Territory**), their territories or possessions; (b) distributed to any US person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)); or (c) distributed to any individual outside a Restricted Territory who is a resident thereof, in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction.

By accepting receipt or attending any delivery of, or electronically accessing, this Presentation, each recipient agrees to be bound by the above limitations and conditions and, in particular represents, warrants and undertakes to the Company that: (i) they will not forward the Presentation to any other person, or reproduce or publish this document, in whole or in part, for any purpose; and (ii) they agree to comply with the contents of this notice.

AGENDA





EMV CAPITAL PLC




INTRODUCTION TO EMV CAPITAL


INTRODUCTION TO EMV CAPITAL PLC

Vision to be a **leading VC investment group** in the deep tech and life sciences sectors

Identifying, investing in, and building **high growth companies** in the UK and internationally

Over £100m Assets Under Management (AUM) at 31 May 2025

- £38.3m in direct balance sheet holdings
- £64.7m in managed and third-party holdings

70+ portfolio companies

Building a sustainable platform to reach next milestone of **£200m+ AUM**

EMV Capital Partners Limited

FCA authorised fundraising and fund management practices

OPERATING MODEL: INCOME GROWTH

ACHIEVE FINANCIAL STABILITY AND INDEPENDENCE

FEE GENERATING: established route to breakeven through fee income

Recurring fund management fees

Corporate finance fundraising fees

Value creation services fees

Exits & Carried Interest

OPERATING MODEL: CAPITAL GROWTH

GROW VALUE OF OUR PORTFOLIO COMPANIES



VENTURE BUILDING
Selective capital efficient balance sheet investment and in-kind services to capitalise upon value opportunities

CORPORATE FINANCE
Facilitating and syndicating external funding for portfolio companies to execute growth and development

PROACTIVE MANAGEMENT
Proactive engagement with company Boards and co-investors – protecting value and driving for returns

VALUE CREATION SERVICES
Supporting a cohort of companies in protecting value and value growth

Support includes investment and exit readiness, business and financial strategy, leadership buildout, corporate collaborations

ROUTES TO EXIT
Proactive drive towards profitable cash exits (partial or full)

To deliver capital gains and carried interest from exits

OPERATING MODEL: AUM GROWTH

SCALE RECURRING MANAGEMENT FEES / CARRIED INTEREST

AUM growth increases carried interest returns, potential and recurring management fees

Key AUM components

- EMV Capital balance sheet investments
- Third party / Managed (investor syndicate)
- Martlet Capital Fund
- EIS Evergreen Fund
- New fund initiatives

OPERATING MODEL: LISTING AS A DIFFERENTIATOR

EMV Capital has made productive use of its quotation

- December 2024 £1.5m placing (at a 15% premium)
- Issuance of shares at a premium to anchor Q-Bot fundraisings
- Ability to selectively issue shares to suppliers or strategic parties
- 'Institutional grade' confidence to co-investors and portfolio companies
- Transparency and governance attractive for Fund LPs/EIS IFAs
- Management team incentivisation



Well positioned to benefit from Mansion House at both PLC and Fund management level

EMV CAPITAL PORTFOLIO

DEEP TECH, LIFE SCIENCES, SUSTAINABILITY

Over £105m raised by the EMV Capital portfolio companies in 2024

Cytovale	Medical biomarker, late clinical
DeepTech Recycling	Recycling of plastic waste, industrial
DName-iT	Lab technology, pre-sales
EPIBONE	Regenerative medicine, early clinical
Glycotest	Liver cancer diagnostics, late clinical
G-Tech Medical	Wearable gut monitor, early clinical
Martlet managed by EMV Capital	Portfolio of 50+ companies managed by EMV Capital
PDS Biotechnology	Immuno-oncology, NASDAQ-listed, late clinical
PointGrab	Smart building automation, sales
ProAxsis	Respiratory diagnostics, sales
q-bot	Robotics, Construction Tech, sales
Quantalx Neuroscience	Medical diagnostics, late clinical
SAGETECH MEDICAL	Waste anaesthetic, sales
sofant technologies	Semiconductors satellite coms, early sales
ventive naturally intelligent ventilation	Heat pump, development Passive ventilation, sales
Vortex BIOSCIENCES	Liquid biopsy oncology, sales
WandaHealth	Digital health monitoring, sales

MARTLET CAPITAL PORTFOLIO

Martlet
managed by EMV Capital

DISCRETIONARY FUND MANAGER TO CAMBRIDGE-BASED VC FUND

Over £171m raised by the Martlet Capital portfolio companies in 2024

converge | CGD CAMBRIDGE GaN DEVICES | Dogtooth | Echion Technologies | FocalPoint

INFINITOPES | myrtle.ai | NoBACZ | nu QUANTUM | OXFORD SPACE SYSTEMS

PARAGRAF | PENCIL Biosciences | PHARMENABLE unlocking chemical space | PX PLASTOMETREX | Plumis

POROTECH | Qkine | SPOTTA | strolll | Xampla

EMV CAPITAL PLC

FINANCIAL HIGHLIGHTS

FINANCIAL HIGHLIGHTS 2024

P&L

Group revenue increased by c.70% to £2.5m (2023: £1.4m)

- Driven by 67% increase in EMV Capital 'core' revenues of £2.0m (2023: £1.2m) - covering c.58% of 'core' costs
- Other subsidiary revenue of £0.5m (ProAxsis)

Adjusted loss at 'core' (i.e. prior to portfolio subsidiaries) of £1.5m (2023: £1.1m)

Group Loss of £3.7m (2023: £2.9m)

- The balance of losses of £2.2m (2023: £1.8m) from subsidiary portfolio companies ProAxsis and Glycotest (including £0.6m non-cash impairment charge for ProAxsis)
- Note subsidiary portfolio companies are funded by third party investment

* Core Group excludes subsidiary portfolio companies (Glycotest and ProAxsis), which are financed by third party investors

‘CORE’ GROUP REVENUE

P&L





- Growing recurring fees from fund management and portfolio monitoring
- Corporate finance fees from syndicated new investments of £8.6m (2023: £6.2m)
- Recurring value creation services fees from Venture Building portfolio
- Significant upside potential from each channel plus carried interest potential

FAIR VALUE GROWTH: DIRECT HOLDINGS

Selective balance sheet investments delivering capital value growth



Growth Prospects for Direct Holdings

- Portfolio company value growth
- Deepening stakes at favourable terms
- New ventures added to the balance sheet

Expected significant capital returns through exits

Note: Directors' FV is calculated according to BVCA standards based on the price of the last third-party externally validated funding round

FAIR VALUE GROWTH: MANAGED AUM

Strong AUM expansion driving recurring revenue and performance fee potential



Growth Prospects for Managed AUM

- Value growth in managed companies
- EIS fund practice scaling organically
- New Fund launches driving AUM

Accumulating carried interest - significant upside

Note: Third-Party Managed FV is calculated according to BVCA standards based on the price of the last externally validated funding round

FAIR VALUE COMPOSITION

AUM of £98.5m at 31 December 2024 and £103m at 31 May 2025





VALUATION METRICS DO NOT REFLECT FULL GROWTH POTENTIAL

Significant discount to current share price



Current fair value (FV) and net asset value (NAV) metrics are inherently retrospective.

They do **not** capture:

- Embedded goodwill within operating businesses
- Future carried interest from fund performance
- Expected growth in the underlying portfolio

As a result, current market capitalisation may underestimate the Group’s real value

EMV CAPITAL PLC



MARTLET CAPITAL MANDATE

OUR MARTLET MANDATE

Martlet
managed by EMV Capital

Expanding AUM and Improving Our Network

EMV CAPITAL APPOINTED AS INVESTMENT MANAGER TO MARTLET CAPITAL, A CAMBRIDGE-BASED VENTURE FUND

- Transaction highlights
    - £24.5m of AUM added (non-dilutive)
    - Carried interest over Martlet Portfolio
    - Recurring fund management fees secured for a minimum of 4 years
    - Access to Cambridge high-tech network
    - Enhanced deal flow and portfolio transactional synergies

- Post appointment progress
    - AUM increased to £25.5m at 31 March 2025 (~10% growth since appointment)
    - Fully integrated into EMV Capital's platform
    - In May 2025, EMV led a £1.3m follow in investment in Martlet Capital



Martlet expands both AUM and reach: reinforcing EMV's position in the UK's deep tech ecosystem

EMV CAPITAL PLC

VENTURE BUILDING PORTFOLIO



VENTURE BUILDING: STRATEGIC APPROACH & VALUE CREATION

£8.5m FV CREATED FROM

£0.4m CASH INVESTMENT &

£0.5m IN-KIND SERVICES

Approach

- Target IP-rich companies needing strategic direction
- Restructure via direct equity (cash and/or in-kind services)
- Deploy EMV Capital shares where appropriate

Growth Support

- Syndicated third-party capital
- Value creation services (commercial, operational, exit-readiness)

Capital efficient model with strong embedded upside

VENTURE BUILDING PROGRAMME – PORTFOLIO HIGHLIGHTS

DeepTech Recycling	DName-iT	ventive naturally intelligent ventilation	Vortex Biosciences	WandaHealth
Plastic Waste Chemical Recycling	**Lab Blood Verification System**	**Heatpump Developer**	**Liquid biopsy cancer diagnostics**	**Digital health monitoring**
Direct stake: Dec 2022 **FV stake increase of £1.8m**	**Direct stake: Dec 2021** **FV stake increase of £1.7m**	**Direct stake: Oct 2022** **FV stake increase of £0.9m**	**Direct stake: Aug 2022** **FV stake increase of £2.8m**	**Direct stake: May 2024** **FV stake increase of £1.3m**
21.2% direct, 29.3% advised	30.7% direct, 19.1% advised	10.4% direct 30.2% advised	22.1% direct,1 3.9% advised	21.2% direct 19.3% advised

EMV CAPITAL PLC

PORTFOLIO HIGHLIGHTS



PORTFOLIO HIGHLIGHTS: SELECTED COMPANIES

	sofant technologies	WandaHealth	DeepTech Recycling
Product / Model	Next gen SatComs antenna Use cases: aircraft, drones, terrestrial, marine	Digital health monitoring Remote patient monitoring Empowers healthcare providers	Chemical recycling platform for plastic waste SPVs with customers to build plants
Market	High-growth mobile, multi-orbit SatComs market expected to reach $14bn by 2033 Civilian and defence applications	$175bn global RPM/Telehealth projected market by 2027 $60bn reimbursement for Medicaid and Medicare	Estimated chemical recycling plant market at £140-210bn
Key 2024 events	Advanced PO by Viasat Progressed European Space Agency contract Successful testing of receive antenna	US Commercial traction Healthcare providers; pharmacy benefit managers Strategic collaborations	Built a pipeline of projects in UK and Scandinavia for several use cases MoU for second project (Scandinavia)
Key 2025 events	Funding round (NSSIF and others) Final Assembly Q4 2025	Funding round Accelerating ARR growth in ARR from several US customers	Funding round (significant uplift) Progress above projects
Company Value	£38.3m	£6.7m	£8.5m
EMVC interest	1.2% direct (FV £0.5m) 27.2% advised (FV £11.8m)	20.2% direct (FV £1.4m) 19.2% advised (FV £1.3m)	21.2% direct (FV £1.8m) 29.3% advised (FV £2.5m)

PORTFOLIO HIGHLIGHTS: SELECTED COMPANIES

	ProAxsis	Glycotest	q-bot
Product / Model	Respiratory diagnostic Sale of kits and lab services	ML-driven biomarker panel test for early-stage liver cancer	Robotics / Construction industry 5,000+ successful retrofit insulation installations
Market	479m estimated cases of COPD globally in 2020	>$800m US and $4bn global market for liver disease diagnostics	$183bn global retrofit systems market grow to $234bn in 2032 TAM of 8m homes (with >5,000 homes undertaken to date)
Key 2024 events	Roadmap to launch NEATstik®2.0 for ongoing at-home monitoring of respiratory disease Imperial College London partnership	Clinical Validation Study: world-leading liver cancer biobank Selection of University of Georgia to drive mass spec application	Strategy pivot toward a partnership and licensing model Turnaround project to decrease costs and streamline operations
Key 2025 events	Anticipated resolution of production issue Resume fundraising Launch COPD clinical study	Continued progress on HCC panel Ongoing fundraising round	Fundraising launched May 2025 Exploring new applications in construction robotics
Company value	£9.0m	£20.9m	estimated £4.8m
EMVC interest	88.5% direct (FV £8.0m) 9.1% advised (FV £0.8m)	• 52.7% direct (FV £11.0m) • 5.8% advised (FV £1.3m)	15.1% direct (FV £0.8m) 21.2% advised (FV £1.8m)

EMV CAPITAL PLC

OUTLOOK & STRATEGIC DIRECTION



OUTLOOK: STRONG PROGRESS IN A VOLATILE MARKET

- **Assets Under Management**
  - AUM grown to £103m (unaudited, post year-end)
  - Further upside potential through:
  - Organic portfolio growth and follow-on rounds
  - New fund launches
  - Expansion of EIS practice
- **Revenue Momentum**
  - Continued growth in recurring fee income
  - Targeting breakeven at core group level
- **Market Environment**
  - Funding and exit conditions remain challenging
  - Strategic focus on value inflection points and selective growth
- **Positioning**
  - Strongly positioned to benefit from:
    - Market recovery
    - Deep Tech and Life Sciences tailwinds
    - Mansion House reforms across fund and PLC levels

Cautiously optimistic, backed by a resilient model, a diversified portfolio, and multiple avenues for value creation.
We expect continued momentum, strategic progress and long-term shareholder value.

SUMMARY

BUILDING A SCALABLE, FUTURE-FOCUSED VENTURE MODEL

Well positioned to capitalise on the evolving venture capital landscape

- **Capital gains potential:** through targeted portfolio exits
- **Carried interest upside:** from third-party fund growth
- **Path to breakeven:** driven by recurring fee income
- **Proven value creation model:** with minimal upfront cash
- **Diverse portfolio:** of 70+ high growth companies

Unlocking public market value from private assets

EMV CAPITAL PLC

APPENDICES

EFFECTIVE BOARD LEADERSHIP

SUPPORTED BY STRONG OPERATIONAL TEAM, VENTURE PARTNERS AND ADVISERS

DR ILIAN ILIEV

CEO

- Substantial shareholder of EMV Capital PLC (14%)
- Founder of EMV Capital Partners
- Experienced investor, negotiator, strategist & hands-on manager
- IP commercialisation
- PhD Cambridge University, Judge Business School

ED HOOPER

Executive Director and GC

- Former Partner of a City-headquartered international law firm
- 20+ years' experience as a solicitor specialising in advising on a broad range of transactions, including fundraisings, M&A, IPOs, joint ventures and restructurings
- Solicitor of the Senior Courts of England and Wales

DR CHARLES SPICER

Non-Executive Chair

- Experienced chair and director in the medtech and life sciences industries
- Previously head of healthcare at Nomura and Numis
- Ex-Chief Executive of MDY Healthcare plc, a healthcare investor
- PhD in History from London University; MA Cambridge University

DR JONATHAN ROBINSON

Senior Independent Director

- Experienced company director, entrepreneur and investor
- Co-founded the publicly quoted Group NBT plc, which ultimately became NetNames Group. Director and COO of the group
- Previously non-executive director of Nominet
- PhD in Materials Engineering from University of Cape Town

PDMRs AND SIGNIFICANT SHAREHOLDERS

Committed management and supportive shareholder base

Shareholder	Shares	Percentage holding	Investor type
Ilian Iliev	3,885,973	13.99%	Director
Ed Hooper	330,000	1.19%	Director
Jonathan Robinson	199,253	0.72%	Director
Charles Spicer	56,286	0.20%	Director
Other PDMRs	223,367	0.80%	PDMR
Total	**4,694,879**	**16.91%**	**-**

Shareholder	Shares	Percentage holding	Investor type
Hargreaves Lansdown Asset Management Nominees*	4,174,101	15.03%	Retail
AB Group, A Beckman SSAS and Lawson Beckman Charitable Trust	4,036,935	14.54%	Family Office
Interactive Investor Services Nominees Limited	2,729,450	9.83%	Retail
Pershing Nominees Limited	2,309,010	8.32%	Retail
James Kight	1,400,000	5.12%	HNWI
APIC Trustees Limited	1,235,493	4.45%	Family Office
Lawshare Nominees Limited	1,208,565	4.35%	Retail
Barclays Direct Investing Nominees Limited	861,497	3.10%	Retail
Total	**17,955,051**	**64.74%**	-

At 10 June 2025

* Net of shares held by Directors and PDMRs

FAIR VALUE OF DIRECTLY HELD PORTFOLIO HOLDINGS

At 31 December 2024

Directors' FV is calculated according to BVCA standards based on the price of the last third-party externally validated funding round

Portfolio Company	Country	Sector	Stage	Holding (%)	Fair Value (m)
EMV Capital	UK	Venture capital	Sales	100%	£3.6
Glycotest	US	Liver cancer diagnostics	Late clinical	52.7%	£11.0
ProAxsis	UK	Respiratory diagnostics	Sales	88.5%	£8.0
Vortex Biotech Holdings Ltd	UK	Liquid biopsy oncology	Sales	22.1%	£3.5
DeepTech Recycling	UK	Recycling	Industrial	21.2%	£1.8
DName-iT	UK	Lab technology	Presales	30.7%	£1.7
PDS Biotechnology - Nasdaq Listed	US	Immuno-oncology	Phase II clinical	2.7%	£1.4
Wanda Health	UK	Digital health monitoring	Sales	20.2%	£1.4
EpiBone	US	Regenerative medicine	Early clinical	1.4%	£1.1
SageTech Medical Equipment	UK	Waste anaesthetic	Commercial	5.0%	£0.9
Ventive	UK	Heat pumps and passive ventilation	Sales	10.1%	£0.9
Q-Bot	UK	Robotics	Sales	15.1%	£0.8
Sofant Technologies	UK	Semiconductors satellite coms	Early sales	1.2%	£0.5
CytoVale	US	Medical biomarker	Late clinical	0.2%	£0.4
G – Tech Medical	US	Wearable gut monitor	Early clinical	3.8%	£0.3
Martlet Capital	UK	Venture capital	Sales	1.4%	£0.2
PointGrab	IL	Smart building automation	Sales	0.4%	£0.1
QuantalX NeuroScience	IL	Medical diagnostics	Late Clinical	0.4%	£0.1
FOx Biosystems	BEL	Research equipment	Sales	3.9%	£0.0
DIRECT ASSETS TOTAL					**£37.7**

FAIR VALUE OF MANAGED PORTFOLIO HOLDINGS

At 31 December 2024

Third-Party Managed FV is calculated according to BVCA standards based on the price of the last externally validated funding round

Portfolio Company	Country	Sector	Stage	Holding (%)	FV (m)
FUND MANAGEMENT					
Martlet Capital Portfolio	UK	Life sciences/DeepTech	Sales	-	£24.5*
EMV Capital Evergreen EIS Fund	UK	Life sciences/DeepTech	Sales	-	£1.3
TOTAL					**£25.8**
MANAGED AND THIRD PARTY					
Sofant Technologies	UK	Semiconductors satellite coms	Early sales	27.2%	£11.8
SageTech Medical Equipment	UK	Waste anaesthetic	Commercial	24.6%	£4.6
PointGrab	IL	Smart building automation	Sales	19.9%	£3.8
Ventive	UK	Heat pumps and passive ventilation	Sales	30.1%	£2.9
DeepTech Recycling Limited	UK	Recycling	Industrial	29.3%	£2.5
Vortex Biotech Holdings Ltd	UK	Liquid biopsy oncology	Sales	13.9%	£2.2
Q-Bot	UK	Robotics	Sales	21.2%	£1.8
Martlet Capital	UK	Venture capital	Sales	6.4%*	£1.6*
Glycotest	US	Liver cancer diagnostics	Late clinical	5.8%	£1.3
Wanda Health	UK	Digital health monitoring	Sales	19.2%	£1.3
DName-iT	UK	Lab technology	Presales	19.1%	£1.1
EpiBone	US	Regenerative medicine	Early clinical	1.1%	£0.9
ProAxsis	UK	Respiratory diagnostics	Sales	9.1%	£0.8
Nanotech Industrial Solutions	US	Material science	Sales	-	£0.0
TOTAL					**£36.6**

* In Martlet Capital the Group holds direct equity investment, syndicated third party monies and fund management stakes which when consolidated for the Groups total AUM have been adjusted for any double count.

EMV CAPITAL PLC



JOIN OUR COMMUNITY

Follow EMV Capital plc on LinkedIn & Twitter

25-28 Old Burlington Street, London W1S 3AN
www.emvcapital.com